Strong Revenue Growth
Total revenues for Q1 2025 were $44 million, marking an approximately 17% increase year-over-year.
Significant Increase in Adjusted EBITDA
Adjusted EBITDA reached $11.6 million, representing a 54% increase over the previous year.
Diversified Portfolio Performance
Growth was driven by increased sales of GLASSIA and KAMRAB in ex-U.S. markets, as well as VARIZIG sales and GLASSIA royalties income.
Guidance for 2025
The company is reiterating its 2025 annual guidance of $178 million to $182 million in revenues and $38 million to $42 million of adjusted EBITDA.
Successful Launch of Biosimilars
Following the first biosimilar product launch in Israel, two additional biosimilars are expected to launch later this year.
Expansion of Plasma Collection
The opening of a new plasma collection center in San Antonio, Texas, which supports over 50 donor beds, is expected to contribute significantly to annual revenues.
Ongoing Phase 3 Clinical Trial
Progress in the pivotal Phase 3 InnovAATe clinical trial for inhaled Alpha-1 Antitrypsin therapy is on track with an interim futility analysis expected by the end of 2025.